Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2025 Mar 31;3(3):CD012572.
doi: 10.1002/14651858.CD012572.pub3.

Withdrawal of antihypertensive drugs in older people

Danijela Gnjidic  1 , Aili V Langford  1   2 , Vanessa Jordan  3 , Mouna Sawan  1 , James P Sheppard  4 , Wade Thompson  5 , Adam Todd  6 , Ingrid Hopper  7   8 , Sarah N Hilmer  9 , Emily Reeve  2   10
Affiliations
Meta-Analysis

Withdrawal of antihypertensive drugs in older people

Danijela Gnjidic et al. Cochrane Database Syst Rev. .

Abstract

Background: Hypertension is an important risk factor for subsequent cardiovascular events, including ischaemic and haemorrhagic stroke, myocardial infarction, and heart failure, as well as chronic kidney disease, cognitive decline, and premature death. Overall, the use of antihypertensive medications has led to a reduction in cardiovascular disease, morbidity rates, and mortality rates. However, the use of antihypertensive medications is also associated with harms, especially in older people, including the development of adverse drug reactions and drug-drug interactions, and can contribute to increasing medication-related burden. As such, discontinuation of antihypertensives may be considered appropriate in some older people.

Objectives: To evaluate the effects of withdrawal of antihypertensive medications used for hypertension or primary prevention of cardiovascular disease in older adults.

Search methods: For this update, we searched the Cochrane Hypertension Specialised Register, CENTRAL (2022, Issue 9), Ovid MEDLINE, Ovid Embase, the WHO ICTRP, and ClinicalTrials.gov up to October 2022. We also conducted reference checking and citation searches, and contacted study authors to identify any additional studies when appropriate. There were no language restrictions on the searches.

Selection criteria: We included randomised controlled trials (RCTs) of withdrawal versus continuation of antihypertensive medications used for hypertension or primary prevention of cardiovascular disease in older adults (defined as 50 years of age and over). Eligible participants were living in the community, residential aged care facilities, or based in hospital settings. We included trials evaluating the complete withdrawal of all antihypertensive medication, as well as those focusing on a dose reduction of antihypertensive medication.

Data collection and analysis: We compared the intervention of discontinuing or reducing the dose of antihypertensive medication to continuing antihypertensive medication using mean differences (MD) and 95% confidence intervals (95% CIs) for continuous variables, and Peto odds ratios (ORs) and 95% CI for binary variables. Our primary outcomes were mortality, myocardial infarction, and the development of adverse drug reactions or adverse drug withdrawal reactions. Secondary outcomes included hospitalisation, stroke, blood pressure (systolic and diastolic), falls, quality of life, and success in withdrawing from antihypertensives. Two review authors independently, and in duplicate, conducted all stages of study selection, data extraction, and quality assessment.

Main results: We identified no new studies in this update. Six RCTs from the original review met the inclusion criteria and were included in the review (1073 participants). Study duration and follow-up ranged from 4 weeks to 56 weeks. Meta-analysis of studies showed that discontinuing antihypertensives, compared to continuing, may result in little to no difference in all-cause mortality (OR 2.08, 95% CI 0.79 to 5.46; P = 0.14, I2 = 0%; 4 studies, 630 participants; low certainty of evidence), and that the evidence is very uncertain about the effect on myocardial infarction (OR 1.86, 95% CI 0.19 to 17.98; P = 0.59, I2 = 0%; 2 studies, 447 participants; very low certainty of evidence). Meta-analysis was not possible for the development of adverse drug reactions and withdrawal reactions; the evidence is very uncertain about the effect of antihypertensive discontinuation on the risk of adverse drug reactions (very low certainty of evidence), and the included studies did not assess adverse drug withdrawal reactions specifically. One study reported on hospitalisations; discontinuing antihypertensives may result in little to no difference in hospitalisation (OR 0.83, 95% CI 0.33 to 2.10; P = 0.70; 1 study, 385 participants; low certainty of evidence). Meta-analysis showed that discontinuing antihypertensives may result in little to no difference in stroke (OR 1.44, 95% CI 0.25 to 8.35; P = 0.68, I2 = 6%; 3 studies, 524 participants; low certainty of evidence). Blood pressure may be higher in the discontinuation group than the continuation group (systolic blood pressure: MD 9.75 mmHg, 95% CI 7.33 to 12.18; P < 0.001, I2 = 67%; 5 studies, 767 participants; low certainty of evidence; and diastolic blood pressure: MD 3.5 mmHg, 95% CI 1.82 to 5.18; P < 0.001, I2 = 47%; 5 studies, 768 participants; low certainty of evidence). No studies reported falls. The sources of bias included selective reporting (reporting bias), lack of blinding of outcome assessment (detection bias), incomplete outcome data (attrition bias), and lack of blinding of participants and personnel (performance bias).

Authors' conclusions: The main conclusions from the 2020 review still apply. Discontinuing antihypertensives may result in little to no difference in mortality, hospitalisation, and stroke. The evidence is very uncertain about the effect of discontinuing antihypertensives on myocardial infarction and adverse drug reactions and adverse drug withdrawal reactions. Discontinuing antihypertensives may result in an increase in blood pressure. There was no information about the effect on falls. The evidence was of low to very low certainty, mainly due to small studies and low event rates. These limitations mean that we cannot draw any firm conclusions about the effect of deprescribing antihypertensives on these outcomes. Future research should focus on populations with the greatest uncertainty of the benefit:risk ratio for the use of antihypertensive medications, such as those with frailty, older age groups, and those taking polypharmacy, and measure clinically important outcomes such as adverse drug events, falls, and quality of life.

PubMed Disclaimer

Conflict of interest statement

Danijela Gnjidic: nothing to declare

Aili Langford: is an Executive Committee member of the Australian Deprescribing Network (ADeN).

Vanessa Jordan: Vanessa Jordan is a sign off editor for Cochrane and a methodology editor for the Cochrane Gynaecology and Fertility Group. However, she was not involved in the editorial process for this article.

Mouna Sawan: nothing to declare

James Sheppard: has received research funding from government and charity organisations to undertake trials of antihypertensive deprescribing, one of which was considered but not included in this review. James Sheppard was not involved in eligibility decisions about, extraction of data from, or risk of bias or GRADE assessment of his own trial(s).

Wade Thompson: nothing to declare

Adam Todd: nothing to declare

Ingrid Hopper: nothing to declare

Sarah N Hilmer: nothing to declare

Emily Reeve: is the Chair of the Australian Deprescribing Network (ADeN) and receives royalties from UpToDate (Wolters Kluwer) for writing a chapter on deprescribing.

Update of

References

References to studies included in this review

Burr 1977 {published data only}
    1. Burr ML, King S, Davies HE, Pathy MS. The effects of discontinuing long-term diuretic therapy in the elderly. Age and Ageing 1977;6(1):38-45. [DOI: 10.1093/ageing/6.1.38] - DOI - PubMed
Langford 1984 {published data only}
    1. Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, et al. Return of hypertension after withdrawal of prolonged antihypertensive therapy, effect of weight loss, sodium reduction, and baseline factors. Transactions of the Association of American Physicians 1984;97:190-6. - PubMed
    1. Thaler L, Wassertheil-Smoller S, Blaufox MD, Oberman A, Langford HG. Effect of withdrawal of antihypertensive drug on depressive mood. American Journal of Hypertension 1993;6:1055-62. - PubMed
Maland 1983 {published data only}
    1. Maland LJ, Lutz LJ, Castle CH. Effects of withdrawing diuretic therapy on blood pressure in mild hypertension. Hypertension 1983;5:539-44. - PubMed
Moonen 2015 {published data only}
    1. Moonen JE, Foster-Dingley JC, De Ruijter W, Van der Grond J, Bertens AS, Van Buchem MA, et al. Effect of discontinuation of antihypertensive treatment in elderly people on cognitive functioning - the DANTE study Leiden: a randomized clinical trial. JAMA Internal Medicine 2015;175:1622-30. [DOI: ] - PubMed
    1. Moonen JEF, Foster-Dingley JC, De Ruijter W, Van der Grond J, De Craen, AJM, Van der Mast RC. Effect of discontinuation of antihypertensive medication on orthostatic hypotension in older persons with mild cognitive impairment: the DANTE study Leiden. Age & Ageing 2016;45:249-55. [DOI: ] - PubMed
    1. NTR2829. Effects of temporary discontinuation of antihypertensive treatment in older patients with cognitive impairment: a randomised controlled trial. https://www.trialregister.nl/trial/2300 (first received 29 March 2011).
Myers 1982 {published data only}
    1. Myers MG, Weingert ME, Fisher RH, Gryfe CI, Shulman HS. Unnecessary diuretic therapy in the elderly. Age and Ageing 1982;11(4):213-21. - PubMed
Walma 1997 {published data only}
    1. Walma EP, Hoes AW, Van Dooren C, Prins A, Van der Does E. Discontinuation of long-term diuretic therapy in the elderly: a successful and safe intervention? A randomized, placebo-controlled, double-blind trial. Huisarts en Wetenschap 1998;41(10):480-5/490.
    1. Walma EP, Hoes AW, Van Dooren C, Prins A, Van der Does E. Withdrawal of long-term diuretic medication in elderly patients: a double blind randomised trial. BMJ (Clinical Research Ed) 1997;315(7106):464-8. - PMC - PubMed

References to studies excluded from this review

Aberg 1989 {published data only}
    1. Aberg H, Tibblin G. Addition of non-pharmacological methods of treatment in patients on antihypertensive drugs: results of previous medication, laboratory tests and life quality. Journal of Internal Medicine 1989;226(1):39-46. [DOI: 10.1111/j.1365-2796.1989.tb01351.x] - DOI - PubMed
ACTRN12622000329763 2022 {published data only}
    1. ACTRN12622000329763. Pharmacy-based screening and quality use of medicines in kidney disease. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12622000329763 (first registered 22 February 2022).
Aharaz 2021 {published data only}
    1. Aharaz A, Rasmussen JH, McNulty HBO, Cyron A, Fabricius PK, Bengaard AK, et al. A collaborative deprescribing intervention in a subacute medical outpatient clinic: a pilot randomized controlled trial. Metabolites 2021;11(4):204. [DOI: 10.3390/metabo11040204] - DOI - PMC - PubMed
Andersen 2008 {published data only}
    1. Andersen K, Weinberger MH, Egan B, Constance CM, Ali MA, Jin J, et al. Comparative efficacy and safety of aliskiren, an oral direct renin inhibitor, and ramipril in hypertension: a 6-month, randomized, double-blind trial. Journal of Hypertension 2008;26(3):589-99. [DOI: 10.1097/HJH.0b013e3282f3ad9a] - DOI - PubMed
Andersen 2009 {published data only}
    1. Andersen K, Weinberger MH, Constance CM, Ali MA, Jin J, Prescott MF, et al. Comparative effects of aliskiren-based and ramipril-based therapy on the renin system during long-term (6 months) treatment and withdrawal in patients with hypertension. Journal of the Renin-Angiotensin-Aldosterone System 2009;10(3):157-67. [DOI: ] - PubMed
Applegate 2020 {published data only}
    1. Applegate WB, Williamson JD, Berlowitz D. Deprescribing antihypertensive medication in elderly adults. JAMA 2020;324:1682. [DOI: 10.1001/jama.2020.16438] - DOI - PubMed
Azizi 2020 {published data only}
    1. Azizi M, Daemen J, Lobo MD, Mahfoud F, Sharp ASP, Schmieder RE, et al. 12-month results from the unblinded phase of the RADIANCE-HTN SOLO trial of ultrasound renal denervation. JACC: Cardiovascular Interventions 2020;13(24):2922-33. [DOI: 10.1016/j.jcin.2021.02.014] - DOI - PubMed
    1. Rader F, Kirtane A, Wang Y, Daemen J, Lurz P, Sayer J, et al. TCT-369 durability of reduced office-measured blood pressure and antihypertensive medication use after ultrasound renal denervation: 24-month results from the RADIANCE-HTN SOLO trial. Journal of the American College of Cardiology 2021;78(19):B152. [DOI: ]
Balsom 2020 {published data only}
    1. Balsom C, Pittman N, King R, Kelly D. Impact of a pharmacist-administered deprescribing intervention on nursing home residents: a randomized controlled trial. International Journal of Clinical Pharmacy 2020;42(4):1153-67. [DOI: 10.1007/s11096-020-01073-6] - DOI - PubMed
Band 2016 {published data only}
    1. Band R, Morton K, Stuart B, Raftery J, Bradbury K, Yao GL, et al. Home and Online Management and Evaluation of Blood Pressure (HOME BP) digital intervention for self-management of uncontrolled, essential hypertension: a protocol for the randomised controlled HOME BP trial. BMJ Open 2016;6(11):e012684. [DOI: 10.1136/bmj.m4858] - DOI - PMC - PubMed
Bauer 2021 {published data only}
    1. Bauer A, Schreinlechner M, Sappler N, Dolejsi T, Tilg H, Aulinger BA, et al. Discontinuation versus continuation of renin-angiotensin-system inhibitors in COVID-19 (ACEI-COVID): a prospective, parallel group, randomised, controlled, open-label trial. Lancet. Respiratory Medicine 2021;9(8):863-72. [DOI: 10.1016/S2213-2600(21)00362-3] - DOI - PMC - PubMed
    1. EUCTR2020-001206-35-AT. Discontinuation of ACE inhibitors in patients with COVID-19 infection. https://trialsearch.who.int/Trial2.aspx?TrialID=EUCTR2020-001206-35-AT (first registered 26 March 2020).
Bawazeer 2022 {published data only}
    1. Bawazeer G, Alsaad S, Almalag H, Alqahtani A, Altulaihi N, Alodhayani A, et al. Impact of specialized clinics on medications deprescribing in older adults: a pilot study in ambulatory care clinics in a teaching hospital. Saudi Pharmaceutical Journal 2022;30(7):1027-35. [DOI: 10.1016/j.jsps.2022.04.012] - DOI - PMC - PubMed
Bayliss 2022 {published data only}
    1. Bayliss EA, Shetterly SM, Drace ML, Norton JD, Maiyani M, Gleason KS, et al. Deprescribing education vs usual care for patients with cognitive impairment and primary care clinicians: the OPTIMIZE pragmatic cluster randomized trial. JAMA Internal Medicine 2022;182(5):534-42. [DOI: 10.1001/jamainternmed.2022.0502] - DOI - PMC - PubMed
Beer 2011 {published data only}
    1. ACTRN12610000865011. Systematic Termination of Pharmaceutical Agents Trial (STOPAT): a pilot randomised trial of stopping drug therapy. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12610000865011 (first registered 15 October 2010.
    1. Beer C, Loh P, Peng YG, Potter K. A pilot randomized controlled trial of deprescribing. Therapeutic Advances in Drug Safety 2011;2(2):37-43. [DOI: 10.1177/2042098611400332] - DOI - PMC - PubMed
Blaufox 1984 {published data only}
    1. Blaufox MD, Langford HG, Oberman A, Hawkins CM, Wassertheil-Smoller SW, Cutter GR. Effect of dietary change on the return of hypertension after withdrawal of prolonged antihypertensive therapy (DISH). Dietary Intervention Study of Hypertension. Journal of Hypertension 1984;2(3 Suppl):S179-81. [PMID: ] - PubMed
Blom 1993 {published data only}
    1. Blom MW, Sommers DK. Placebo substitution for methyldopa in geriatric hypertensive patients. South African Medical Journal (Suid-Afrikaanse Tydskrif Vir Geneeskunde) 1993;83(5):335-6. [PMID: ] - PubMed
Bogaerts 2022 {published and unpublished data}
    1. Bogaerts J, Gussekloo J, De Jong-Schmit B, Achterberg W, Poortvliet R. The DANTON study - discontinuation of antihypertensive treatment in older people with dementia living in a nursing home: results of a randomized controlled trial. Conference: 31st Scientific Meeting of the European Society of Hypertension, ESH 2022. Athens, Greece. Journal of Hypertension 2022;40(Suppl 1):e1. [DOI: 10.1097/01.hjh.0000835304.61321.dc] - DOI
    1. NTR7573. Discontinuation of antihypertensive treatment in older people with dementia living in a nursing home. http://www.who.int/trialsearch/Trial2.aspx?TrialID=NTR7573 (first registered 15 October 2018).
Bonnet‐Zamponi 2013 {published data only}
    1. Bonnet-Zamponi D, d'Arailh L, Konrat C, Delpierre S, Lieberherr D, Lemaire A, et al. Drug-related readmissions to medical units of older adults discharged from acute geriatric units: results of the Optimization of Medication in AGEd multicenter randomized controlled trial. Journal of the American Geriatrics Society 2013;61(1):113-21. [DOI: 10.1111/jgs.12037] - DOI - PubMed
Bosch 2021 {published data only}
    1. Bosch J, Lonn EM, Jung H, Zhu J, Liu L, Lopez-Jaramillo P, et al. Lowering cholesterol, blood pressure, or both to prevent cardiovascular events: results of 8.7 years of follow-up of Heart Outcomes Evaluation Prevention (HOPE)-3 study participants. European Heart Journal 2021;42(31):2995-3007. [DOI: 10.1093/eurheartj/ehab225] - DOI - PMC - PubMed
Bovee 2020 {published data only}
    1. Bovee DM, Visser WJ, Middel I, De Mik-van Egmond A, Greupink R, Masereeuw R, et al. A randomized trial of distal diuretics versus dietary sodium restriction for hypertension in chronic kidney disease. Journal of the American Society of Nephrology 2020;31(3):650-62. [DOI: 10.1681/ASN.2019090905] - DOI - PMC - PubMed
Boye 2017 {published data only}
    1. Boyé ND, Van der Velde N, De Vries OJ, Van Lieshout EM, Hartholt KA, Mattace-Raso FU, et al. Effectiveness of medication withdrawal in older fallers: results from the improving medication prescribing to reduce risk of falls (IMPROveFALL) trial. Age and Ageing 2017;46(1):142-6. [DOI: 10.1093/ageing/afw161] - DOI - PubMed
Cateau 2021 {published data only}
    1. Cateau D, Ballabeni P, Niquille A. Effects of an interprofessional deprescribing intervention in Swiss nursing homes: the Individual Deprescribing Intervention (IDeI) randomised controlled trial. BMC Geriatrics 2021;21(1):655. [DOI: 10.1186/s12877-021-02465-7] - DOI - PMC - PubMed
Cohen 2021 {published data only}
    1. Cohen JB, Hanff TC, William P, Sweitzer N, Rosado-Santander NR, Medina C, et al. Continuation versus discontinuation of renin-angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial. Lancet Respiratory Medicine 2021;9(3):275-84. [DOI: 10.1016/S2213-2600(20)30558-0] - DOI - PMC - PubMed
Crisafulli 2021 {published data only}
    1. Crisafulli S, Luxi N, Coppini R, Capuano A, Scavone C, Zinzi A, et al. Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. BMC Family Practice 2021;22(1):208. [DOI: 10.1186/s12875-021-01557-y] - DOI - PMC - PubMed
CTRI/2021/01/030199 {published data only}
    1. CTRI/2021/01/030199. Continuation or stopping antihypertensives in patients undergoing non-cardiac surgery. https://trialsearch.who.int/Trial2.aspx?TrialID=CTRI/2021/01/030199.
Curtin 2020 {published data only}
    1. Curtin D, Jennings E, Daunt R, Curtin S, Randles M, Gallagher P, et al. Deprescribing in Older People Approaching End of Life: a Randomized Controlled Trial Using STOPPFrail Criteria. Journal of the American Geriatrics Society 2020;68(4):762-9. [DOI: 10.1111/jgs.16278] - DOI - PubMed
Ekbom 1992 {published data only}
    1. Ekbom TSA. Risks of Hypertension in the Elderly (Doctoral Dissertation). Lund: Lund University, 1992.
ENOS Trial Investigators 2015 {published data only}
    1. ENOS Trial Investigators. Efficacy of nitric oxide, with or without continuing antihypertensive treatment, for management of high blood pressure in acute stroke (ENOS): a partial-factorial randomised controlled trial. Lancet 2015;385(9968):617-28. [DOI: 10.1016/S0140-6736(14)61121-1] - DOI - PMC - PubMed
    1. Krishnan K, Scutt P, Woodhouse L, Adami A, Becker JL, Cala LA, et al. Continuing versus stopping prestroke antihypertensive therapy in acute intracerebral hemorrhage: a subgroup analysis of the efficacy of Nitric Oxide in Stroke trial. Journal of Stroke and Cerebrovascular Diseases 2016;25(5):1017-26. [DOI: ] - PMC - PubMed
    1. Woodhouse LJ, Appleton JP, Scutt P, Everton L, Wilkinson G, Caso V, et al. Effect of continuing versus stopping pre-stroke antihypertensive agents within 12 h on outcome after stroke: a subgroup analysis of the efficacy of nitric oxide in stroke (ENOS) trial. EClinicalMedicine 2022;44:101274. [DOI: 10.1016/j.eclinm.2022.101274] - DOI - PMC - PubMed
Gulla 2018 {published data only}
    1. Gulla C, Flo E, Kjome RL, Husebo BS. Deprescribing antihypertensive treatment in nursing home patients and the effect on blood pressure. Journal of Geriatric Cardiology 2018;15(4):275-83. [DOI: 10.11909/j.issn.1671-5411.2018.04.011] - DOI - PMC - PubMed
Guthrie 2002 {published data only}
    1. Guthrie R, Reeves RA. Omapatrilat provides long-term control of hypertension: a randomized trial of treatment withdrawal. Journal of Clinical Hypertension 2002;4(3):169-72. [DOI: 10.1111/j.1524-6175.2002.01400.x] - DOI - PMC - PubMed
Hansen 1983 {published data only}
    1. Hansen AG, Jensen H, Laugesen LP, Petersen A. Withdrawal of antihypertensive drugs in the elderly. Acta Medica Scandinavica 1983;676:178-85. [DOI: ] - PubMed
He 2018 {published data only}
    1. He WJ, Zhong C, Xu T, Wang D, Sun Y, Bu X, et al. Early antihypertensive treatment and clinical outcomes in acute ischemic stroke: subgroup analysis by baseline blood pressure. Journal of Hypertension 2018;36(6):1372-81. [DOI: 10.1097/HJH.0000000000001690] - DOI - PMC - PubMed
Hung 2014 {published data only}
    1. Hung W. Self-monitoring and self-titration of antihypertensive medications result in better systolic blood pressure control. Journal of Clinical Outcomes Management 2014;21(10):444-8.
Jondeau 2009 {published data only}
    1. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. European Heart Journal 2009;30(18):2186-92. [DOI: 10.1093/eurheartj/ehp323] - DOI - PubMed
Juraschek 2022 {published data only}
    1. Juraschek SP, Cluett JL, Belanger MJ, Anderson TS, Ishak A, Sahni S, et al. Effects of antihypertensive deprescribing strategies on blood pressure, adverse events, and orthostatic symptoms in older adults: results from TONE. American Journal of Hypertension 2022;35(4):337-46. [DOI: 10.1093/ajh/hpab171] - DOI - PMC - PubMed
    1. Kostis JB, Espeland MA, Appel L, Johnson KC, Pierce J, Wofford JL, Trial of nonpharmacologic interventions in the elderly (TONE) Cooperative Research Group. Does withdrawal of antihypertensive medication increase the risk of cardiovascular events? American Journal of Cardiology 1998;82:1501-8. [DOI: 10.1016/s0002-9149(98)00694-8] - DOI - PubMed
    1. NCT00000535. Trial of Nonpharmacologic Interventions in Elderly (TONE). https://clinicaltrials.gov/show/NCT00000535.
Kraut 2022 {published data only}
    1. Kraut R, Sadowski C, Youngson E, Faulder D, Korownyk C, Bakal J, et al. Antihypertensive deprescribing in long-term care: a randomized controlled trial (OPTIMIZEBP). Conference: Preventing Overdiagnosis Conference 2022. Calgary, AB Canada. BMJ Evidence-Based Medicine 2022;27(Suppl 1):A26-27.
    1. NCT05047731. Antihypertensive Deprescribing in Long-term Care (OptimizeBP). https://clinicaltrials.gov/show/NCT05047731.
Kua 2021 {published data only}
    1. Kua CH, Yeo CY, Tan PC, Char CW, Tan CW, Mak V, et al. Association of deprescribing with reduction in mortality and hospitalization: a pragmatic stepped-wedge cluster-randomized controlled trial. Journal of the American Medical Directors Association 2021;22(1):82-89.e3. [DOI: 10.1016/j.jamda.2020.03.012] - DOI - PubMed
Langford 1985 {published data only}
    1. Langford HG, Blaufox MD, Oberman A, Hawkins CM, Curb JD, Cutter GR, et al. Dietary therapy slows the return of hypertension after stopping prolonged medication. JAMA 1985;253(5):657-64. [PMID: ] - PubMed
Lewin 2012 {published data only}
    1. Lewin A, Lasseter KC, Dong F, Whalen JC. Nebivolol withdrawal results in blood pressure returning toward pretreatment levels, but without rebound symptoms: phase IV randomized trial. Journal of the American Society of Hypertension 2012;6:228-36. [DOI: ] - PubMed
Luymes 2018 {published data only}
    1. Luymes CH, Poortvliet RK, Van Geloven N, De Waal MW, Drewes YM, Blom JW, et al. Deprescribing preventive cardiovascular medication in patients with predicted low cardiovascular disease risk in general practice - the ECSTATIC study: a cluster randomised non-inferiority trial. BMC Medicine 2018;16(1):5. [DOI: 10.1186/s12916-017-0988-0] - DOI - PMC - PubMed
Manning 2015 {published data only}
    1. Manning LS, Mistri AK, Potter J, Rothwell PM, Robinson TG. Short-term blood pressure variability in acute stroke: post hoc analysis of the controlling hypertension and hypotension immediately post-stroke and continue or stop post-stroke antihypertensives collaborative study trials. Stroke 2015;46:1518-24. [DOI: ] - PubMed
McDonald 2022 {published data only}
    1. McDonald EG, Wu PE, Rashidi B, Wilson MG, Bortolussi-Courval E, Atique A, et al. The MedSafer study-electronic decision support for deprescribing in hospitalized older adults: a cluster randomized clinical trial. JAMA Internal Medicine 2022;182(3):265-73. [DOI: 10.1001/jamainternmed.2021.7429] - DOI - PMC - PubMed
Medical Research Council Working Party 1986 {published data only}
    1. Medical Research Council Working Party on Mild Hypertension. Course of blood pressure in mild hypertensives after withdrawal of long term antihypertensive treatment. British Medical Journal (Clinical Research Ed) 1986;293(6553):988-92. [DOI: 10.1136/bmj.293.6553.988] - DOI - PMC - PubMed
Morgan 1994 {published data only}
    1. Morgan T, Hopper H, Anderson A, Carricks L, Jones E, Johns J, et al. Can drug therapy be stopped in elderly hypertensive patients? Cardiology in the Elderly 1994;2(2):119-25.
Morselli 2022 {published data only}
    1. Morselli F, Khong TK. Short-term effect of deprescribing antihypertensives in older people. Drug and Therapeutics Bulletin 2022;60(8):118-9. [DOI: 10.1136/dtb.2022.000030] - DOI - PubMed
NCT00219063 {published data only}
    1. NCT00219063. A clinical study to compare an aliskiren based hypertensive regimen with a ramipril based one followed by a randomized withdrawal. clinicaltrials.gov/ct2/show/NCT00219063.
NCT00785512 {published data only}
    1. NCT00785512. A study on the long-term efficacy of nebivolol after withdrawal of therapy. clinicaltrials.gov/ct2/show/NCT00785512.
NCT05307666 {published data only}
    1. NCT05307666. MinMed: do older adults do better with less medication. https://clinicaltrials.gov/show/NCT05307666.
NCT05585268 {published data only}
    1. NCT05585268. Electronic decision support for deprescribing in patients on hemodialysis (MedSafer-HD). https://clinicaltrials.gov/show/NCT05585268.
Nelson 2003 {published data only}
    1. Nelson MR, Reid CM, Krum H, Ryan P, Wing LM, McNeil JJ, Management Committee, Second Australian National Blood Pressure Study. Short-term predictors of maintenance of normotension after withdrawal of antihypertensive drugs in the second Australian National Blood Pressure Study (ANBP2). American Journal of Hypertension 2003;16:39-45. [DOI: 10.1016/s0895-7061(02)03143-6] - DOI - PubMed
Neusy 1989 {published data only}
    1. Neusy AJ, Lowenstein J. Blood pressure and blood pressure variability following withdrawal of propranolol and clonidine. Journal of Clinical Pharmacology 1989;29:18-24. [DOI: 10.1002/j.1552-4604.1989.tb03232.x] - DOI - PubMed
NHF 1981 {published data only}
    1. National Heart Foundation. Treatment of mild hypertension in the elderly. A study initiated and administered by the National Heart Foundation (NHF) of Australia. Medical Journal of Australia 1981;2:398-402. [PMID: ] - PubMed
Ohkuma 2022 {published data only}
    1. Ohkuma T, Harris K, Cooper M, Grobbee DE, Hamet P, Harrap S, et al. Short-term changes in serum potassium and the risk of subsequent vascular events and mortality: results from a randomized controlled trial of ACE inhibitors. Clinical Journal of the American Society of Nephrology 2022;17(8):1139-49. [DOI: 10.2215/CJN.00180122] - DOI - PMC - PubMed
Pazan 2018 {published data only}
    1. Farhad P, Heinrich B, Helmut F, Christel W, Christina T, Alexandra KT, et al. Changes in prescription patterns in older hospitalized patients: the impact of FORTA on disease-related over- and under-treatments. European Journal of Clinical Pharmacology 2018;74(3):339-47. [DOI: 10.1007/s00228-017-2383-3] - DOI - PubMed
    1. Wehling M, Burkhardt H, Frohnhofen H, Weiss C, Throm C, Kuhn-Thiel A, et al. FORTAMET study: the impact of FORTA on disease-related over-and under-treatment in older hospitalized patients. Conference: 14th International Congress of the European Geriatric Medicine Society, EuGMS 2018. Germany. European Geriatric Medicine 2018;9(Suppl 1):S47.
Ponten 1982 {published data only}
    1. Ponten J, Biber B, Henriksson BA, Hjalmarson A, Jonsteg C, Lundberg D. β-receptor blockade and neurolept anaesthesia. Withdrawal vs continuation of long-term therapy in gall-bladder and carotid artery surgery. Acta Anaesthesiologica Scandinavica 1982;26:576-88. [DOI: ] - PubMed
Popa 1995 {published data only}
    1. Popa G, Voiculescu V, Popa C, Stanescu A, Nistorescu A, Jipescu I. Stroke and hypertension. Antihypertensive therapy withdrawal. Romanian Journal of Neurology & Psychiatry 1995;33:29-35. - PubMed
Potter 2016 {published data only}
    1. ACTRN12611000370909. Deprescribing in frail older people: a randomised controlled trial. https://trialsearch.who.int/Trial2.aspx?TrialID=ACTRN12611000370909. - PMC - PubMed
    1. Potter K, Flicker L, Page A, Etherton-Beer C. Deprescribing in frail older people: a randomised controlled trial. PLOS ONE 2016;11(3):e0149984. [DOI: 10.1371/journal.pone.0149984] - DOI - PMC - PubMed
Ramirez‐Jimenez 2018 {published data only}
    1. Ramirez-Jimenez M, Morales-Palomo F, Ortega JF, Mora-Rodriguez R. Effects of intense aerobic exercise and/or antihypertensive medication in individuals with metabolic syndrome. Scandinavian Journal of Medicine & Science in Sports 2018;28(9):2042-51. [DOI: 10.1111/sms.13218] - DOI - PubMed
Ramirez‐Jimenez 2021 {published data only}
    1. Ramirez Jimenez M, Morales-Palomo F, Moreno-Cabanas A, Alvarez-Jimenez L, Ortega JF, Mora-Rodriguez R. Additive blood-pressure lowering effect of aerobic training on antihypertensive medication in metabolic syndrome individuals. Conference: European Meeting on Hypertension and Cardiovascular Protection and International Society of Hypertension, ESH-ISH 2021. Virtual. Journal of Hypertension 2021;39(Suppl 1):e393.
    1. Ramirez-Jimenez M, Morales-Palomo F, Moreno-Cabanas A, Alvarez-Jimenez L, Ortega JF, Mora-Rodriguez R. Effects of antihypertensive medication and high-intensity interval training in hypertensive metabolic syndrome individuals. Scandinavian Journal of Medicine & Science in Sports 2021;31(7):1411-9. [DOI: 10.1111/sms.13949] - DOI - PubMed
Robinson 2010 {published data only}
    1. COSSACS Trial Group. COSSACS (Continue or Stop post-Stroke Antihypertensives Collaborative Study): rationale and design. Journal of Hypertension 2005;23(2):455-8. [DOI: ] - PubMed
    1. Eames PJ, Potter JF, Robinson TG. Continue or stop post-stroke antihypertensives collaborative study (COSSACS). In: International Stroke Conference. 2005.
    1. Ferrari J. Effects of antihypertensive treatment after acute stroke in the Continue or Stop post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Journal fur Neurologie, Neurochirurgie und Psychiatrie 2010;11:85-6. - PubMed
    1. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, et al: COSSACS Investigators. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurology 2010;9:767-75. [DOI: ] - PubMed
    1. Robinson TG, Potter JF. The continue or stop post-stroke antihypertensives collaborative study (COSSACS). Cerebrovascular Diseases 2003;16:Suppl 4.
Ruoff 1986 {published data only}
    1. Ruoff G. Effect of withdrawal of terazosin therapy in patients with hypertension. American Journal of Medicine 1986;80:35-41. - PubMed
Sharma 2022 {published data only}
    1. Sharma A, Elharram M, Afilalo J, Flannery A, Afilalo M, Tselios C, et al. A randomized controlled trial of renin-angiotensin-aldosterone system inhibitor management in patients admitted in hospital with COVID-19. American Heart Journal 2022;247:76-89. [DOI: 10.1016/j.ahj.2022.01.015] - DOI - PMC - PubMed
Sheppard 2020 {published data only}
    1. Burt J, Sheppard J, Lown M, Mant J, Little P, McManus RJ. OPtimising Treatment for MIld Systolic hypertension in the Elderly (OPTiMISE): a protocol for a randomised controlled trial. Pharmacoepidemiology and Drug Safety 2017;26(Suppl 1):6-7. [DOI: 10.1136/bmjopen-2018-022930] - DOI
    1. Jowett S, Kodabuckus S, Ford GA, Hobbs FD, Lown M, Mant J, et al. Cost-effectiveness of antihypertensive deprescribing in primary care: a markov modelling study using data from the optimise trial. Hypertension 2022;79(5):1122-31. [DOI: 10.1161/HYPERTENSIONAHA] - DOI - PMC - PubMed
    1. Sheppard J, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Short-term safety of antihypertensive medication reduction in multi-morbid patients with mild hypertension: the optimise randomised controlled non-inferiority trial. Journal of Hypertension 2021;39(Suppl 1):e369-70.
    1. Sheppard J, Lown M, Burt J, Temple E, Ford G, Hobbs R, et al. Optimal drugs for medication reduction: secondary analysis of the optimise medication reduction trial. Conference: European Meeting on Hypertension and Cardiovascular Protection and International Society of Hypertension, ESH-ISH 2021. Virtual. Journal of Hypertension 2021;39(Suppl 1):e52.
    1. Sheppard JP, Burt J, Lown M, Temple E, Lowe R, Fraser R, et al. Effect of antihypertensive medication reduction vs usual care on short-term blood pressure control in patients with hypertension aged 80 years and older: the OPTIMISE randomized clinical trial. JAMA 2020;323(20):2039-51. [DOI: 10.1001/jama.2020.4871] - DOI - PMC - PubMed
Stange 2013 {published data only}
    1. Stange D, Kriston L, von-Wolff A, Baehr M, Dartsch DC. Reducing cardiovascular medication complexity in a German university hospital: effects of a structured pharmaceutical management intervention on adherence. Journal of Managed Care Pharmacy 2013;19(5):396-407. [DOI: 10.18553/jmcp.2013.19.5.396] - DOI - PMC - PubMed
Szam 1981 {published data only}
    1. Szam I, Hollo J. Antihypertensive effect of guanfacine: long-term 'once-a-day' treatment and sudden withdrawal. Clinical Science 1981;61(Suppl 7):469s-71s. [DOI: 10.1042/cs061469s] - DOI - PubMed
Vaur 1998 {published data only}
    1. Vaur L, Bobrie G, Dutrey-Dupagne C, Dubroca I, Vaisse B, D'Yvoire MB, et al. Short-term effects of withdrawing angiotensin converting enzyme inhibitor therapy on home self-measured blood pressure in hypertensive patients. American Journal of Hypertension 1998;11:165-73. [DOI: 10.1016/s0895-7061(97)00420-2] - DOI - PubMed
Veterans Administration Cooperative 1975 {published data only}
    1. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Return of elevated blood pressure after withdrawal of antihypertensive drugs. Circulation 1975;51:1107-13. [DOI: 10.1161/01.cir.51.6.1107] - DOI - PubMed
Wachtell 2022 {published data only}
    1. Wachtell K, Julius S, Okin PM, Greve AM, Devereux RB, Oparil S, et al. Cardiovascular outcomes in hypertensive patients who discontinue study medication in a large outcome trial. The life study. Hypertension 2022;79:AP221. [DOI: ]
Xu 2017 {published data only}
    1. Xu T, Zhang Y, Bu X, Wang D, Sun Y, Chen CS, et al, CATIS Investigators. Blood pressure reduction in acute ischemic stroke according to time to treatment: a subgroup analysis of the China Antihypertensive Trial in Acute Ischemic Stroke trial. Journal of Hypertension 2017;35(6):1244-51. [DOI: 10.1097/HJH.0000000000001288] - DOI - PMC - PubMed
    1. Zhang R, Zhong C, Zhang Y, Xie X, Zhu Z, Wang A, et al. Immediate antihypertensive treatment for patients with acute ischemic stroke with or without history of hypertension: a secondary analysis of the CATIS randomized clinical trial. JAMA Network Open 2019;2(7):e198103. [DOI: 10.1001/jamanetworkopen.2019.8103] - DOI - PMC - PubMed
Yang 2021 {published data only}
    1. Yang YF, Zhu YJ, Long YQ, Liu HY, Shan XS, Feng XM, et al. Withholding vs. continuing angiotensin-converting enzyme inhibitors or angiotensin receptor blockers before non-cardiac surgery in older patients: study protocol for a multicenter randomized controlled trial. Frontiers in Medicine 2021;8:654700. [DOI: 10.3389/fmed.2021.654700] - DOI - PMC - PubMed
Zhang 2019 {published data only}
    1. Zhang Y, Liang M, Sun C, Qu G, Shi T, Min M, et al. Effect of intensive lowering of systolic blood pressure treatment on heart failure events: a meta-analysis of randomized controlled studies. Journal of Human Hypertension 2019;33(9):648-57. [DOI: 10.1038/s41371-019-0221-z] - DOI - PubMed

Additional references

Albasri 2021
    1. Albasri A, Hattle M, Koshiaris C, Dunnigan A, Paxton B, Fox SE, et al. Association between antihypertensive treatment and adverse events: systematic review and meta-analysis. BMJ 2021;372:n189. [DOI: 10.1136/bmj.n189] - DOI - PMC - PubMed
Bogaerts 2022
    1. Bogaerts JM, Ballmoos LM, Achterberg WP, Gussekloo J, Streit S, Ploeg MA, et al. Do we AGREE on the targets of antihypertensive drug treatment in older adults: a systematic review of guidelines on primary prevention of cardiovascular diseases. Age and Ageing 2022;51(1):afab192. [DOI: 10.1093/ageing/afab192] - DOI - PMC - PubMed
Chatzis 2023
    1. Chatzis DG, Magounaki K, Pantazopoulos I, Beltsios ET, Katsi V, Tsioufis KP. Current management of hypertension in older adults. Drugs & Aging 2023;40(5):407-16. [DOI: 10.1007/s40266-023-01013-9] - DOI - PubMed
Crisafulli 2021
    1. Crisafulli S, Luxi N, Coppini R, Capuano A, Scavone C, Zinzi A, et al. Anti-hypertensive drugs deprescribing: an updated systematic review of clinical trials. BMC Family Practice 2021;22:1-11. [DOI: 10.1186/s12875-021-01557-y] - DOI - PMC - PubMed
Dunlay 2016
    1. Dunlay SM, Chamberlain AM. Multimorbidity in older patients with cardiovascular disease. Current Cardiovascular Risk Reports 2016;10:1-9. [DOI: 10.1007/s12170-016-0491-8] - DOI - PMC - PubMed
Ekbom 1994
    1. Ekbom T, Lindholm LH, Odén A, Dahlöf B, Hansson L, Wester PO, et al. A 5-year prospective, observational study of the withdrawal of antihypertensive treatment in elderly people. Journal of Internal Medicine 1994;235(6):581-8. [DOI: 10.1111/j.1365-2796.1994.tb01265.x] - DOI - PubMed
Froom 1997
    1. Froom J, Trilling JS, Yeh SS, Gomolin IH, Filkin AM, Grimson RC. Withdrawal of antihypertensive medications. Journal of the American Board of Family Practice 1997;10(4):249-58. [PMID: ] - PubMed
Fryar 2017
    1. Fryar CD, Ostchega Y, Hales CM, Zhang G, Kruszon-Moran D. Hypertension prevalence and control among adults: United States, 2015-2016. https://www.cdc.gov/nchs/products/databriefs/db289.htm (accessed prior to 28 May 2020). - PubMed
Gnjidic 2021
    1. Gnjidic D, Reeve E. Deprescribing: what do we know, and where to next? British Journal of Clinical Pharmacology 2021;87(3):722-4. [DOI: 10.1111/bcp.14525] - DOI - PubMed
Gnjidic 2022
    1. Gnjidic D, Johansson M, Meng DM, Farrell B, Langford A, Reeve E. Achieving sustainable healthcare through deprescribing. Cochrane Database of Systematic Reviews 2022, Issue 10. [DOI: 10.1002/14651858.ED000159] - DOI - PMC - PubMed
Goshgarian 2019
    1. Goshgarian C, Gorelick PB. Perspectives on the relation of blood pressure and cognition in the elderly. Trends in Cardiovascular Medicine 2019;29(1):12-8. [DOI: 10.1016/j.tcm.2018.05.011] - DOI - PubMed
Higgins 2017
    1. Higgins JP, Altman DG, Sterne JA (editors). Chapter 8: Assessing risk of bias in included studies. In: Higgins JPT, Churchill R, Chandler J, Cumpston MS (editors). Cochrane Handbook for Systematic Reviews of Interventions version 5.2.0 (updated June 2017), Cochrane, 2017. Available from training.cochrane.org/handbook/archive/v5.2.
Ikeda 2014
    1. Ikeda N, Sapienza D, Guerrero R, Aekplakorn W, Naghavi M, Mokdad AH, et al. Control of hypertension with medication: a comparative analysis of national surveys in 20 countries. Bulletin of the World Health Organization 2014;92(1):10-9C. [DOI: 10.2471/BLT.13.121954] - DOI - PMC - PubMed
Iyer 2008
    1. Iyer S, Naganathan V, McLachlan AJ, Le Couteur DG. Medication withdrawal trials in people aged 65 years and older. Drugs & Aging 2008;25(12):1021-31. [DOI: 10.2165/0002512-200825120-00004] - DOI - PubMed
Johansson 2019
    1. Johansson M, Bero L, Bonfill X, Bruschettini M, Garner S, Glenton C, et al. Cochrane sustainable healthcare: evidence for action on too much medicine. Cochrane Database of Systematic Reviews 2019, Issue 12. [DOI: 10.1002/14651858.ED000143] - DOI - PMC - PubMed
Jongstra 2016
    1. Jongstra S, Harrison JK, Quinn TJ, Richard E. Antihypertensive withdrawal for the prevention of cognitive decline. Cochrane Database of Systematic Reviews 2016, Issue 11. Art. No: CD011971. [DOI: 10.1002/14651858.CD011971.pub2] - DOI - PMC - PubMed
Lee 2022
    1. Lee GB, Etherton-Beer C, Hosking SM, Pasco JA, Page AT. The patterns and implications of potentially suboptimal medicine regimens among older adults: a narrative review. Therapeutic Advances in Drug Safety 2022;13:20420986221100117. [DOI: 10.1177/20420986221100117] - DOI - PMC - PubMed
Mancia 2023
    1. Mancia G, Kreutz R, Brunström M, Burnier M, Grassi G, Januszewicz A, et al. 2023 ESH guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). Journal of Hypertension 2023;41(12):1874-2071. [DOI: 10.1097/HJH.0000000000003480] - DOI - PubMed
Mensah 2017
    1. Mensah GA, Wei GS, Sorlie PD, Fine LJ, Rosenberg Y, Kaufmann PG, et al. Decline in cardiovascular mortality: possible causes and implications. Circulation Research 2017;120(2):366-80. [DOI: 10.1161/CIRCRESAHA.116.309115] - DOI - PMC - PubMed
Moher 2009
    1. Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Annals of Internal Medicine 2009;151(4):264-9. [DOI: 10.7326/0003-4819-151-4-200908180-00135] - DOI - PubMed
Morel 2022
    1. Morel T, Nguyen-Soenen J, Thompson W, Fournier JP. Development and validation of search filters to identify articles on deprescribing in Medline and Embase. BMC Medical Research Methodology 2022;22(1):1-9. [DOI: 10.1186/s12874-022-01515-x] - DOI - PMC - PubMed
Moriarty 2022
    1. Moriarty F, Thompson W, Boland F. Methods for evaluating the benefit and harms of deprescribing in observational research using routinely collected data. Research in Social and Administrative Pharmacy 2022;18:2269-75. [DOI: 10.1016/j.sapharm.2021.05.007] - DOI - PubMed
Musini 2019
    1. Musini VM, Tejani AM, Bassett K, Puil L, Wright JM. Pharmacotherapy for hypertension in adults 60 years or older. Cochrane Database of Systematic Reviews 2019, Issue 6. Art. No: CD000028. [DOI: 10.1002/14651858.CD000028.pub3] - DOI - PMC - PubMed
National Heart Foundation of Australia 2016
    1. National Heart Foundation of Australia. Guideline for the diagnosis and management of hypertension in adults – 2016. www.heartfoundation.org.au/getmedia/c83511ab-835a-4fcf-96f5-88d770582ddc... (accessed prior to 28 May 2020). [ISBN: 978-174345-110-6]
Nelson 2001
    1. Nelson M, Reid C, Krum H, McNeil J. A systematic review of predictors of maintenance of normotension after withdrawal of antihypertensive drugs. American Journal of Hypertension 2001;14(2):98-105. [DOI: 10.1016/s0895-7061(00)01246-2] - DOI - PubMed
NICE 2016
    1. National Institute for Health and Care Excellence (NICE). Multimorbidity: clinical assessment and management [ng56]. https://www.nice.org.uk/guidance/ng56/resources/multimorbidity-clinical-....
NICE 2019
    1. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [ng136]. www.nice.org.uk/guidance/ng136. - PubMed
NICE 2022
    1. National Institute for Health and Care Excellence (NICE). Hypertension in adults: diagnosis and management [ng136]. https://www.nice.org.uk/guidance/ng136/resources/hypertension-in-adults-.... - PubMed
Oktora 2019
    1. Oktora MP, Denig P, Bos JH, Schuiling-Veninga CC, Hak E. Trends in polypharmacy and dispensed drugs among adults in the Netherlands as compared to the United States. PLOS ONE 2019;14(3):e0214240. [DOI: 10.1371/journal.pone.0214240] - DOI - PMC - PubMed
Page 2016
    1. Page AT, Clifford RM, Potter K, Schwartz D, Etherton‐Beer CD. The feasibility and effect of deprescribing in older adults on mortality and health: a systematic review and meta‐analysis. British Journal of Clinical Pharmacology 2016;82(3):583-623. [DOI: doi: 10.1111/bcp.12975] - PMC - PubMed
Page 2019
    1. Page AT, Falster MO, Litchfield M, Pearson SA, Etherton‐Beer C. Polypharmacy among older Australians, 2006–2017: a population‐based study. Medical Journal of Australia 2019;211(2):71-5. [DOI: 10.5694/mja2.50244] - DOI - PubMed
Parekh 2017
    1. Parekh N, Page A, Ali K, Davies K, Rajkumar C. A practical approach to the pharmacological management of hypertension in older people. Therapeutic Advances in Drug Safety 2017;8(4):117-32. [DOI: 10.1177/2042098616682721] - DOI - PMC - PubMed
Publish or Perish 2022 [Computer program]
    1. Publish or Perish. Version 8.8. Harzing AW, 2022. Available at https://harzing.com/resources/publish-or-perish.
Reeve 2014a
    1. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. The benefits and harms of deprescribing. Medical Journal of Australia 2014;201:386-9. [DOI: 10.5694/mja13.00200] - DOI - PubMed
Reeve 2014b
    1. Reeve E, Shakib S, Hendrix I, Roberts MS, Wiese MD. Review of deprescribing processes and development of an evidence based, patient-centred deprescribing process. British Journal of Clinical Pharmacology 2014;78(4):738-47. [DOI: doi: 10.1111/bcp.12386] - PMC - PubMed
Reeve 2015
    1. Reeve E, Wiese M, Mangoni A. Alterations in drug disposition in older adults. Expert Opinion On Drug Metabolism and Toxicology 2015;11(4):491-508. [DOI: 10.1517/17425255.2015.1004310] - DOI - PubMed
Reeve 2017
    1. Reeve E, Thompson W, Farrell B. Deprescribing: a narrative review of the evidence and practical recommendations for recognizing opportunities and taking action. European Journal of Internal Medicine 2017;38:3-11. [DOI: 10.1016/j.ejim.2016.12.021] - DOI - PubMed
RevMan 2024 [Computer program]
    1. Review Manager (RevMan). Version 7.12.0. The Cochrane Collaboration, 2024. Available at https://revman.cochrane.org.
Sawan 2021
    1. Sawan MJ, Moga DC, Ma MJ, Ng JC, Johnell K, Gnjidic D. The value of deprescribing in older adults with dementia: a narrative review. Expert Review of Clinical Pharmacology 2021;14(11):1367-82. [DOI: 10.1080/17512433.2021.1961576] - DOI - PubMed
Sawan 2022
    1. Sawan MJ, Jeon YH, Hilmer SN, Chen TF. Perspectives of residents on shared decision making in medication management: a qualitative study. International Psychogeriatrics 2022;34(10):929-39. [DOI: 10.1017/S1041610222000205] - DOI - PubMed
Schünemann 2011a
    1. Schünemann HJ, Oxman AD, Higgins JP, Vist GE, Glasziou P, Guyatt GH (editors). Chapter 11: Presenting results and 'summary of findings' tables. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Schünemann 2011b
    1. Schünemann HJ, Oxman AD, Vist GE, Higgins JP, Deeks JJ, Glasziou P, et al. Chapter 12: Interpreting results and drawing conclusions. In: Higgins JPT, Green S, editor(s). Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0 (updated March 2011). The Cochrane Collaboration, 2011. Available from training.cochrane.org/handbook/archive/v5.1/.
Scott 2015
    1. Scott IA, Hilmer SN, Reeve E, Potter K, Le Couteur D, Rigby D, et al. Reducing inappropriate polypharmacy: the process of deprescribing. JAMA Internal Medicine 2015;175:827-34. [DOI: 10.1001/jamainternmed.2015.0324] - DOI - PubMed
Scott 2019
    1. Scott IA, Hilmer SN, Le Couteur DG. Going beyond the guidelines in individualising the use of antihypertensive drugs in older patients. Drugs and Aging 2019;36(8):675-85. [DOI: 10.1007/s40266-019-00683-8] - DOI - PubMed
Shenkin 2017
    1. Shenkin SD, Harrison JK, Wilkinson T, Dodds RM, Ioannidis JP. Systematic reviews: guidance relevant for studies of older people. Age & Ageing 2017;46(5):722-8. [DOI: 10.1093/ageing/afx185] - DOI - PMC - PubMed
Sheppard 2022
    1. Sheppard JP, Benetos A, McManus RJ. Antihypertensive deprescribing in older adults: a practical guide. Current Hypertension Reports 2022;24:571-80. [DOI: 10.1007/s11906-022-01215-3] - DOI - PMC - PubMed
Sheppard 2023
    1. Sheppard JP, Koshiaris C, Stevens R, Lay-Flurrie S, Banerjee A, Bellows BK, et al. The association between antihypertensive treatment and serious adverse events by age and frailty: a cohort study. PLOS Medicine 2023;20(4):e1004223. [DOI: 10.1371/journal.pmed.1004223] - DOI - PMC - PubMed
Steinman 2006
    1. Steinman MA, Landefeld CS, Rosenthal GE, Berthenthal D, Sen S, Kaboli PJ. Polypharmacy and prescribing quality in older people. Journal of the American Geriatrics Society 2006;54(10):1516-23. [DOI: 10.1111/j.1532-5415.2006.00889.x] - DOI - PubMed
Sterne 2014
    1. Sterne JA, Higgins JP, Reeves BC, the development group for ACROBAT-NRSI. A Cochrane risk of bias assessment tool: for non-randomised studies of interventions (ACROBAT-NRSI). Available from www.riskofbias.info (accessed prior to 28 May 2020);(1.0.0).
Unger 2020
    1. Unger T, Borghi C, Charchar F, Khan NA, Poulter NR, Prabhakaran D, et al. 2020 International Society of Hypertension global hypertension practice guidelines. Hypertension 2020;75:1334–57. [DOI: 10.1161/HYPERTENSIONAHA] - DOI - PubMed
Van Der Velde 2007
    1. Van Der Velde N, Stricker BH, Pols HA, Van Der Cammen TJ. Risk of falls after withdrawal of fall‐risk‐increasing drugs: a prospective cohort study. British Journal of Clinical Pharmacology 2007;63(2):232-7. [DOI: 10.1111/j.1365-2125.2006.02736.x] - DOI - PMC - PubMed
Van der Wardt 2017
    1. Van der Wardt V, Harrison JK, Welsh T, Conroy S, Gladman J. Withdrawal of antihypertensive medication: a systematic review. Journal of Hypertension 2017;35(9):1742. [DOI: 10.1097/HJH.0000000000001405] - DOI - PMC - PubMed
Wastesson 2018
    1. Wastesson JW, Morin L, Tan EC, Johnell K. An update on the clinical consequences of polypharmacy in older adults: a narrative review. Expert Opinion on Drug Safety 2018;17(12):1185-96. [DOI: 10.1080/14740338.2018.1546841] - DOI - PubMed
Weir 2022
    1. Weir KR, Ailabouni NJ, Schneider CR, Hilmer SN, Reeve E. Consumer attitudes towards deprescribing: a systematic review and meta-analysis. The Journals of Gerontology: Series A (Medical Sciences) 2022;77(5):1020-34. [DOI: 10.1093/gerona/glab222] - DOI - PMC - PubMed
Whelton 2018
    1. Whelton PK, Carey RM, Aronow WS, Casey DE, Collins KJ, Himmelfarb DC, et al, American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS /APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Journal of the American College of Cardiology 2018;71:2199-269. [DOI: 10.1161/HYP.0000000000000080] - DOI
Williams 2018
    1. Williams B, Mancia G, Spiering W, Agabiti Rosei E, Azizi M, Burnier M, et al, Task force for the management of arterial hypertension of the European Society of Cardiology and the European Society of Hypertension. 2018 ESC/ESH guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). European Heart Journal 2018;33(1):3021-104. [DOI: 10.1093/eurheartj/ehy339] - DOI
Woolcott 2009
    1. Woolcott JC, Richardson KJ, Wiens MO, Patel B, Marin J, Khan KM, et al. Meta-analysis of the impact of 9 medication classes on falls in elderly persons. Archives of Internal Medicine 2009;169(21):1952-60. [DOI: 10.1001/archinternmed.2009.357] - DOI - PubMed

References to other published versions of this review

Babar 2017
    1. Babar ZU, Gammie TM, Gnjidic D, Reeve E, Jordan-Cole V, Hilmer SN, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database of Systematic Reviews 2017, Issue 2. Art. No: CD012572. [DOI: 10.1002/14651858.CD012572] - DOI - PMC - PubMed
Reeve 2020
    1. Reeve E, Jordan V, Thompson W, Sawan M, Todd A, Gammie TM, et al. Withdrawal of antihypertensive drugs in older people. Cochrane Database of Systematic Reviews 2020, Issue 6. Art. No: CD012572. [DOI: 10.1002/14651858.CD012572.pub2] - DOI - PMC - PubMed

Substances

LinkOut - more resources